Fexofenadine differs from terfenadine in that: A. It undergoes high first pass metabolism in liver B. It is a prodrug C. It does not block cardiac delayed rectifier K+ channels D. It has high affinity for central H1 receptors

Fexofenadine differs from terfenadine in that: A. It undergoes high first pass metabolism in liver B. It is a prodrug C. It does not block cardiac delayed rectifier K+ channels D. It has high affinity for central H1 receptors
by

1 Answer

Answer :

C. It does not block cardiac delayed rectifier K+ channels
by

Related questions

The capacity of an antihistaminic to produce sedation depends on the following except: A. Relative affinity for central versus peripheral H1 receptors B. Ability to penetrate blood-brain barrier C. Individual susceptibility D. Ratio of H1:H2 blockade produced by the drug

Description : The capacity of an antihistaminic to produce sedation depends on the following except: A. Relative affinity for central versus peripheral H1 receptors B. Ability to penetrate blood-brain barrier C. Individual susceptibility D. Ratio of H1:H2 blockade produced by the drug

Last Answer : D. Ratio of H1:H2 blockade produced by the drug

The capacity of an antihistaminic to produce sedation depends on the following except: A. Relative affinity for central versus peripheral H1 receptors B. Ability to penetrate blood-brain barrier C. Individual susceptibility D. Ratio of H1:H2 blockade produced by the drug

Description : The capacity of an antihistaminic to produce sedation depends on the following except: A. Relative affinity for central versus peripheral H1 receptors B. Ability to penetrate blood-brain barrier C. Individual susceptibility D. Ratio of H1:H2 blockade produced by the drug

Last Answer : D. Ratio of H1:H2 blockade produced by the drug

Select the H1 antihistaminic which is used topically in the nose for allergic rhinitis: A. Loratadine B. Cetirizine C. Fexofenadine D. Azelastine

Description : Select the H1 antihistaminic which is used topically in the nose for allergic rhinitis: A. Loratadine B. Cetirizine C. Fexofenadine D. Azelastine

Last Answer : D. Azelastine

The following H1 antihistaminic has additional anti 5-HT, anticholinergic, sedative and appetite stimulating properties: A. Promethazine B. Terfenadine C. Cyproheptadine D. Hydroxyzine

Description : The following H1 antihistaminic has additional anti 5-HT, anticholinergic, sedative and appetite stimulating properties: A. Promethazine B. Terfenadine C. Cyproheptadine D. Hydroxyzine

Last Answer : C. Cyproheptadine

The following H1 antihistaminic has additional anti 5-HT, anticholinergic, sedative and appetite stimulating properties: A. Promethazine B. Terfenadine C. Cyproheptadine D. Hydroxyzine

Description : The following H1 antihistaminic has additional anti 5-HT, anticholinergic, sedative and appetite stimulating properties: A. Promethazine B. Terfenadine C. Cyproheptadine D. Hydroxyzine

Last Answer : C. Cyproheptadine

Erythromycin should not be given to a patient being treated with terfenadine because: A. Erythromycin induces the metabolism of terfenadine B. Dangerous ventricular arrhythmias can occur C. Terfenadine inhibitis metabolism of erythromycin D. Terfenadine antagonizes the antimicrobial action of erythromycin

Description : Erythromycin should not be given to a patient being treated with terfenadine because: A. Erythromycin induces the metabolism of terfenadine B. Dangerous ventricular arrhythmias ... Terfenadine inhibitis metabolism of erythromycin D. Terfenadine antagonizes the antimicrobial action of erythromycin

Last Answer : B. Dangerous ventricular arrhythmias can occur

The action of histamine that is not mediated through H1 receptors is: A. Release of EDRF from vascular endothelium resulting in vasodilatation B. Direct action on vascular smooth muscle causing vasodilatation C. Bronchoconstriction D. Release of catecholamines from adrenal medulla

Description : The action of histamine that is not mediated through H1 receptors is: A. Release of EDRF from vascular endothelium resulting in vasodilatation B. Direct action on vascular smooth muscle causing vasodilatation C. Bronchoconstriction D. Release of catecholamines from adrenal medulla

Last Answer : B. Direct action on vascular smooth muscle causing vasodilatation

The action of histamine that is not mediated through H1 receptors is: A. Release of EDRF from vascular endothelium resulting in vasodilatation B. Direct action on vascular smooth muscle causing vasodilatation C. Bronchoconstriction D. Release of catecholamines from adrenal medulla

Description : The action of histamine that is not mediated through H1 receptors is: A. Release of EDRF from vascular endothelium resulting in vasodilatation B. Direct action on vascular smooth muscle causing vasodilatation C. Bronchoconstriction D. Release of catecholamines from adrenal medulla

Last Answer : B. Direct action on vascular smooth muscle causing vasodilatation

High anticholinergic property is present in the following antihistaminic: A. Diphenhydramine B. Astemizole C. Cetirizine D. Terfenadine

Description : High anticholinergic property is present in the following antihistaminic: A. Diphenhydramine B. Astemizole C. Cetirizine D. Terfenadine

Last Answer : A. Diphenhydramine

High anticholinergic property is present in the following antihistaminic: A. Diphenhydramine B. Astemizole C. Cetirizine D. Terfenadine

Description : High anticholinergic property is present in the following antihistaminic: A. Diphenhydramine B. Astemizole C. Cetirizine D. Terfenadine

Last Answer : A. Diphenhydramine

During Phase 2 of action potential in cardiac cell, depolarizing current through calcium channels is balanced by (a) Delayed rectifier potassium current (b) outward chloride channel (c) Both (a) and (b) (d) None of the above

Description : During Phase 2 of action potential in cardiac cell, depolarizing current through calcium channels is balanced by (a) Delayed rectifier potassium current (b) outward chloride channel (c) Both (a) and (b) (d) None of the above

Last Answer : Ans: A

The capacity of an antihistaminic to produce sedation depends on the following except (a) Relative affinity for central versus peripheral H1 receptors (b) Ability to penetrate blood-brain barrier (c) Individual susceptibility (d) Ratio of H1 : H2 blockade produced by the drug

Description : The capacity of an antihistaminic to produce sedation depends on the following except (a) Relative affinity for central versus peripheral H1 receptors (b) Ability to penetrate blood-brain barrier (c) Individual susceptibility (d) Ratio of H1 : H2 blockade produced by the drug

Last Answer : Ans: D

While prescribing a first generation H1 antihistaminic the patient should be advised to avoid: A. Driving motor vehicles B. Consuming processed cheese C. Strenuous physical exertion D. All of the above

Description : While prescribing a first generation H1 antihistaminic the patient should be advised to avoid: A. Driving motor vehicles B. Consuming processed cheese C. Strenuous physical exertion D. All of the above

Last Answer : A. Driving motor vehicles

While prescribing a first generation H1 antihistaminic the patient should be advised to avoid: A. Driving motor vehicles B. Consuming processed cheese C. Strenuous physical exertion D. All of the above

Description : While prescribing a first generation H1 antihistaminic the patient should be advised to avoid: A. Driving motor vehicles B. Consuming processed cheese C. Strenuous physical exertion D. All of the above

Last Answer : A. Driving motor vehicles

The conventional H1 antihistaminics possess the following additional properties except: A. Local anaesthetic B. Vasopressor C. Antiarrhythmic D. Catecholamine potentiating

Description : The conventional H1 antihistaminics possess the following additional properties except: A. Local anaesthetic B. Vasopressor C. Antiarrhythmic D. Catecholamine potentiating

Last Answer : B. Vasopressor

Which of the following is a selective H1 receptor agonist: A. 4-methyl histamine B. Impromidine C. 2-Thiazolyl ethylamine D. Chlorpheniramine

Description : Which of the following is a selective H1 receptor agonist: A. 4-methyl histamine B. Impromidine C. 2-Thiazolyl ethylamine D. Chlorpheniramine

Last Answer : C. 2-Thiazolyl ethylamine

Benefit afforded by certain H1 antihistaminics in the following condition is not based on antagonism of histamine: A. Dermographism B. Insect bite C. Common cold D. Seasonal hay fever

Description : Benefit afforded by certain H1 antihistaminics in the following condition is not based on antagonism of histamine: A. Dermographism B. Insect bite C. Common cold D. Seasonal hay fever

Last Answer : C. Common cold

H1 antihistaminics are beneficial in: A. All types of allergic disorders B. Certain type I allergic reactions only C. Certain type IV allergic reactions only D. Bronchial asthma

Description : H1 antihistaminics are beneficial in: A. All types of allergic disorders B. Certain type I allergic reactions only C. Certain type IV allergic reactions only D. Bronchial asthma

Last Answer : B. Certain type I allergic reactions only

The conventional H1 antihistaminics possess the following additional properties except: A. Local anaesthetic B. Vasopressor C. Antiarrhythmic D. Catecholamine potentiating

Description : The conventional H1 antihistaminics possess the following additional properties except: A. Local anaesthetic B. Vasopressor C. Antiarrhythmic D. Catecholamine potentiating

Last Answer : B. Vasopressor

Which of the following is a selective H1 receptor agonist: A. 4-methyl histamine B. Impromidine C. 2-Thiazolyl ethylamine D. Chlorpheniramine

Description : Which of the following is a selective H1 receptor agonist: A. 4-methyl histamine B. Impromidine C. 2-Thiazolyl ethylamine D. Chlorpheniramine

Last Answer : C. 2-Thiazolyl ethylamine

The ‘amine’ ergot alkaloid differs from ‘amino acid’ ergot alkaloid in that it has: A. High oral bioavailability B. Better CNS penetrability C. Weaker oxytocic action D. Strong anti-5-HT action

Description : The ‘amine’ ergot alkaloid differs from ‘amino acid’ ergot alkaloid in that it has: A. High oral bioavailability B. Better CNS penetrability C. Weaker oxytocic action D. Strong anti-5-HT action

Last Answer : A. High oral bioavailability

Dihydroergotamine (DHE) differs from ergotamine in the following respect: A. It is a more potent oxytocic B. It has antiemetic property C. It has high oral bioavailability D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Description : Dihydroergotamine (DHE) differs from ergotamine in the following respect: A. It is a more potent oxytocic B. It has antiemetic property C. It has high oral bioavailability D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Last Answer : D. It is a more potent α adrenergic blocker and less potent vasoconstrictor

Aspirin is contraindicated in pregnant women near term because: A. Labour may be delayed and prolonged B. Blood loss during delivery may be more C. Foetus may suffer premature closure of ductus arteriosus D. All of the above risks

Description :  Aspirin is contraindicated in pregnant women near term because: A. Labour may be delayed and prolonged B. Blood loss during delivery may be more C. Foetus may suffer premature closure of ductus arteriosus D. All of the above risks

Last Answer : D. All of the above risks

Aspirin produces analgesia by: A. Preventing sensitization of peripheral pain receptors B. Affecting gating of pain impulses at spinal level C. Raising pain threshold at subcortical level D. Both ‘A’ and ‘C’ are correct

Description : Aspirin produces analgesia by: A. Preventing sensitization of peripheral pain receptors B. Affecting gating of pain impulses at spinal level C. Raising pain threshold at subcortical level D. Both ‘A’ and ‘C’ are correct

Last Answer : D. Both ‘A’ and ‘C’ are correct

Phenylbutazone should be used only in patients not responding to other nonsteroidal antiinflammatory drugs (NSAIDs) because: A. It has lower antiinflammatory efficacy than other NSAIDs B. It has potential to cause agranulocytosis C. It has weak analgesic action D. It alters the protein binding and metabolism of many drugs

Description : Phenylbutazone should be used only in patients not responding to other nonsteroidal antiinflammatory drugs (NSAIDs) because: A. It has lower antiinflammatory efficacy than other NSAIDs B. It has potential ... It has weak analgesic action D. It alters the protein binding and metabolism of many drugs

Last Answer : B. It has potential to cause agranulocytosis

Select the organic nitrate which undergoes minimal first-pass metabolism in the liver (a) Glyceryl trinitrate (b) Isosorbide dinitrate (c) Isosorbide mononitrate (d) Erythrityl tetranitrate

Description : Select the organic nitrate which undergoes minimal first-pass metabolism in the liver (a) Glyceryl trinitrate (b) Isosorbide dinitrate (c) Isosorbide mononitrate (d) Erythrityl tetranitrate

Last Answer : Ans: C

Select the organic nitrate which undergoes minimal first-pass metabolism in the liver: A. Glyceryl trinitrate B. Isosorbide dinitrate C. Isosorbide mononitrate D. Erythrityl tetranitrate

Description : Select the organic nitrate which undergoes minimal first-pass metabolism in the liver: A. Glyceryl trinitrate B. Isosorbide dinitrate C. Isosorbide mononitrate D. Erythrityl tetranitrate

Last Answer : C. Isosorbide mononitrate

Select the drug that undergoes extensive first-pass metabolism in the liver: A. Phenobarbitone B. Propranolol C. Phenylbutazone D. Theophylline

Description : Select the drug that undergoes extensive first-pass metabolism in the liver: A. Phenobarbitone B. Propranolol C. Phenylbutazone D. Theophylline

Last Answer : B. Propranolol

Select the drug that undergoes extensive first-pass metabolism in the liver: A. Phenobarbitone B. Propranolol C. Phenylbutazone D. Theophylline

Description : Select the drug that undergoes extensive first-pass metabolism in the liver: A. Phenobarbitone B. Propranolol C. Phenylbutazone D. Theophylline

Last Answer : B. Propranolol

Relative to fexofenadine, diphenhydramine is more likely to (a) Be used for treatment of asthma (b) Be used for treatment of gastroesophageal reflux disease (c) Cause cardiac arrhythmias in overdose (d) Have efficacy in the prevention of motion sickness (e) Increase the serum concentration of warfarin

Description : Relative to fexofenadine, diphenhydramine is more likely to (a) Be used for treatment of asthma (b) Be used for treatment of gastroesophageal reflux disease (c) Cause cardiac arrhythmias in ... ) Have efficacy in the prevention of motion sickness (e) Increase the serum concentration of warfarin

Last Answer : Ans: D

Choose the correct statement(s) about dofetilide: A. It is a pure class III antiarrhythmic B. It has no adrenergic/cholinergic receptor blocking property C. It selectively depresses the rapid component of delayed rectifier K+ current in myocardial fibres D. All of the above

Description : Choose the correct statement(s) about dofetilide: A. It is a pure class III antiarrhythmic B. It has no adrenergic/cholinergic receptor blocking property C. It selectively depresses the rapid component of delayed rectifier K+ current in myocardial fibres D. All of the above

Last Answer : D. All of the above

A 35-year-old male presented with an attack of acute gout. He was treated with a 10 day course of naproxen. His blood uric acid level is high. What future line of treatment is most appropriate: A. No regular medication. Treat attacks of acute gout when they occur with naproxen. B. Regular long-term treatment with naproxen C. Regular long-term treatment with allopurinol D. Start with allopurinol + naproxen for 2 months followed by long-term allopurinol treatment

Description : A 35-year-old male presented with an attack of acute gout. He was treated with a 10 day course of naproxen. His blood uric acid level is high. What future line of treatment is ... treatment with allopurinol D. Start with allopurinol + naproxen for 2 months followed by long-term allopurinol treatment

Last Answer : D. Start with allopurinol + naproxen for 2 months followed by long-term allopurinol treatment

The following is true of clarithromycin except: A. It produces less gastric irritation and pain than erythromycin B. It is the most active macrolide antibiotic against Helicobacter pylori C. It does not interact with terfenadine or cisapride to cause cardiac arrhythmias D. It exhibits dose dependent elimination kinetics

Description : The following is true of clarithromycin except: A. It produces less gastric irritation and pain than erythromycin B. It is the most active macrolide antibiotic against Helicobacter pylori ... terfenadine or cisapride to cause cardiac arrhythmias D. It exhibits dose dependent elimination kinetics

Last Answer : C. It does not interact with terfenadine or cisapride to cause cardiac arrhythmias

Erythromycin should not be given to patient being treated with terfenadine because (a) Erythromycin induces the metabolism of terfenadine (b) Dangerous ventricular arrhythmias can occur (c) Terfenadine inhibits metabolism of erythromycin (d) Terfenadine antagonizes the antimicrobal action of erythromycin

Description : Erythromycin should not be given to patient being treated with terfenadine because (a) Erythromycin induces the metabolism of terfenadine (b) Dangerous ventricular arrhythmias can occur ... inhibits metabolism of erythromycin (d) Terfenadine antagonizes the antimicrobal action of erythromycin

Last Answer : Ans: B

Potassium therapy tends to counteract the cardiac toxicity of digitalis by: A. Reducing the affinity of sarcolemal Na+ K+ATPase for digitalis B. Suppressing ectopic automaticity enhanced by digitalis C. Promoting A-V conduction D. Both 'A' and 'B' are correct

Description : Potassium therapy tends to counteract the cardiac toxicity of digitalis by: A. Reducing the affinity of sarcolemal Na+ K+ATPase for digitalis B. Suppressing ectopic automaticity enhanced by digitalis C. Promoting A-V conduction D. Both 'A' and 'B' are correct

Last Answer : D. Both 'A' and 'B' are correct

Bioavailability differences among oral formulations of a drug are most likely to occur if the drug: A. Is freely water soluble B. Is completely absorbed C. Is incompletely absorbed D. Undergoes little first-pass metabolism

Description : Bioavailability differences among oral formulations of a drug are most likely to occur if the drug: A. Is freely water soluble B. Is completely absorbed C. Is incompletely absorbed D. Undergoes little first-pass metabolism

Last Answer : C. Is incompletely absorbed

Bioavailability differences among oral formulations of a drug are most likely to occur if the drug: A. Is freely water soluble B. Is completely absorbed C. Is incompletely absorbed D. Undergoes little first-pass metabolism

Description : Bioavailability differences among oral formulations of a drug are most likely to occur if the drug: A. Is freely water soluble B. Is completely absorbed C. Is incompletely absorbed D. Undergoes little first-pass metabolism

Last Answer : C. Is incompletely absorbed

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Description : Labetalol differs from propranolol in that: A. It has additional α1 blocking property B. It is a selective β1 blocker C. It does not undergo first pass metabolism D. All of the above

Last Answer : A. It has additional α1 blocking property

Select the first choice drug for acute gout: A. Cochicine B. Indomethacin C. Allopurinol D. Dexamethasone

Description : Select the first choice drug for acute gout: A. Cochicine B. Indomethacin C. Allopurinol D. Dexamethasone

Last Answer : B. Indomethacin

Autacoids differ from hormones in that: A. Autacoids are involved only in the causation of pathological states B. Autacoids do not have a specific cell/tissue of origin C. Autacoids generally act locally at the site of generation and release D. Both ‘B’ and ‘C’ are correct

Description : Autacoids differ from hormones in that: A. Autacoids are involved only in the causation of pathological states B. Autacoids do not have a specific cell/tissue of origin C. Autacoids generally act locally at the site of generation and release D. Both ‘B’ and ‘C’ are correct

Last Answer : D. Both ‘B’ and ‘C’ are correct

Allopurinol has a therapeutic effect in the following conditions except: A. Radiotherapy induced hyperuricaemia B. Hydrochlorothiazide induced hyperuricaemia C. Acute gouty arthritis D. Kala-azar

Description : Allopurinol has a therapeutic effect in the following conditions except: A. Radiotherapy induced hyperuricaemia B. Hydrochlorothiazide induced hyperuricaemia C. Acute gouty arthritis D. Kala-azar

Last Answer : C. Acute gouty arthritis

Allopurinol is indicated in the following category of chronic gout patients: A. Over producers of uric acid B. Under excretors of uric acid C. Those with tophi and/or renal urate stones D. All of the above

Description : Allopurinol is indicated in the following category of chronic gout patients: A. Over producers of uric acid B. Under excretors of uric acid C. Those with tophi and/or renal urate stones D. All of the above

Last Answer : D. All of the above

Select the drug which is used in chronic gout but is not uricosuric: A. Probenecid B. Phenylbutazone C. Sulfinpyrazone D. Allopurinol

Description : Select the drug which is used in chronic gout but is not uricosuric: A. Probenecid B. Phenylbutazone C. Sulfinpyrazone D. Allopurinol

Last Answer : D. Allopurinol

Probenecid has the following action(s): A. Uricosuric B. Analgesic C. Antiinflammatory D. Both ‘A’ and ‘C’

Description : Probenecid has the following action(s): A. Uricosuric B. Analgesic C. Antiinflammatory D. Both ‘A’ and ‘C’

Last Answer : A. Uricosuric

The most important dose-limiting adverse effect of colchicine is: A. Sedation B. Kidney damage C. Diarrhoea D. Muscle paralysis

Description : The most important dose-limiting adverse effect of colchicine is: A. Sedation B. Kidney damage C. Diarrhoea D. Muscle paralysis

Last Answer : C. Diarrhoea

Select the drug which is neither analgesic, nor antiinflammatory, nor uricosuric, but is highly efficacious in acute gout: A. Prednisolone B. Colchicine C. Naproxen D. Sulfinpyrazone

Description : Select the drug which is neither analgesic, nor antiinflammatory, nor uricosuric, but is highly efficacious in acute gout: A. Prednisolone B. Colchicine C. Naproxen D. Sulfinpyrazone

Last Answer : B. Colchicine

Nonsteroidal antiinflammatory drugs are more commonly used than colchicine in acute gout because: A. They are more effective B. They act more rapidly C. They have additional uricosuric action D. They are better tolerated

Description : Nonsteroidal antiinflammatory drugs are more commonly used than colchicine in acute gout because: A. They are more effective B. They act more rapidly C. They have additional uricosuric action D. They are better tolerated

Last Answer : D. They are better tolerated

What is true of disease modifying antirheumatic drugs: A. Their beneficial effect is manifest only after 1-3 months of therapy B. The disease does not recurr once they induce remission C. They are to be used life long D. Concurrent use of more than one disease modifying drug is not recommended

Description : What is true of disease modifying antirheumatic drugs: A. Their beneficial effect is manifest only after 1-3 months of therapy B. The disease does not recurr once they induce remission C. They are to be used life long D. Concurrent use of more than one disease modifying drug is not recommended

Last Answer : A. Their beneficial effect is manifest only after 1-3 months of therapy

Disease modifying antirheumatic drugs are indicated in rheumatoid arthritis: A. In place of NSAIDs in patients who donot tolerate the latter B. Along with NSAIDs in patients with progressive disease C. Only when NSAIDs fail to afford symptomatic relief D. In all patients irrespective of disease status/ concurrent medication

Description : Disease modifying antirheumatic drugs are indicated in rheumatoid arthritis: A. In place of NSAIDs in patients who donot tolerate the latter B. Along with NSAIDs in patients with progressive ... to afford symptomatic relief D. In all patients irrespective of disease status/ concurrent medication

Last Answer : B. Along with NSAIDs in patients with progressive disease